PlainRecalls
FDA Drug Low Class III Terminated

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD

Reported: March 13, 2019 Initiated: February 28, 2019 #D-0519-2019

Product Description

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD

Reason for Recall

Failed Dissolution Specifications; 9-monthstability timepoint

Details

Units Affected
a) 3,072 bottles; b) 2,688 bottles
Distribution
Product was distributed to one customer who may have further distributed the product.
Location
Salisbury, MD

Frequently Asked Questions

What product was recalled?
BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD. Recalled by Jubilant Cadista Pharmaceuticals, Inc.. Units affected: a) 3,072 bottles; b) 2,688 bottles.
Why was this product recalled?
Failed Dissolution Specifications; 9-monthstability timepoint
Which agency issued this recall?
This recall was issued by the FDA Drug on March 13, 2019. Severity: Low. Recall number: D-0519-2019.